Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. Issue 32 (12th August 2022)

• Record Type: Journal Article
• Authors: Obinata, Daisuke; Funakoshi, Daigo; Sakurai, Fuminori; Yoshizawa, Tsuyoshi; Mochida, Junichi; Yamaguchi, Kenya; Takahashi, Satoru
• Is Part Of: Medicine. Volume 101:Issue 32(2022)
• Page Start: e29510
• Publication Date: 2022-08-12
• Subjects: mTOR inhibitor -- nivolumab -- renal cell carcinoma -- tyrosine kinase inhibitor; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029510
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : This study aimed to clarify the real-world efficacy of sequential nivolumab for treating metastatic renal cancer after first-line molecular targeting therapy. Patients were divided into two groups (2014–2016 and 2017–2020) according to the year when they started primary treatment with molecular targeted drugs (MTDs). We compared the overall survival of patients and investigated a contributing factor for survival. The mean duration of overall survival was significantly longer in the 2017–2020 group (44.0 months) than in the 2014–2016 group (8.5 months). Univariate analysis showed that nivolumab treatment was a significant prognostic factor ( P = .0021). Patients treated with nivolumab as second-line therapy had a significantly higher 5-year survival rate compared to that of other patients (70% vs 32%). In addition, the time from commencement of MTDs to switch to nivolumab was significantly shorter in the 2017–2020 group compared to the 2014–2016 group (8.94 vs 34.12 months, P = .03). In our study, cases with first-line MTDs had markedly prolonged outcomes after the 2017 guideline update, and sequential nivolumab with prompt switching to nivolumab was an important factor.